Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10432875 | 0.86 | MAPT (0.61) | ALDH1A1KMT2AHDAC2HDAC8HDAC6 | |
| SCHEMBL105766 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KEAP1FFAR1KMT2AMEN1 | |
| SCHEMBL5598970 | 0.84 | ALDH1A1 (0.61) | ALDH1A1KEAP1FFAR1KMT2AMEN1 | |
| SCHEMBL691726 | 0.82 | ALDH1A1 (0.59) | ALDH1A1KEAP1FFAR1KMT2AMEN1 | |
| SCHEMBL28601916 | 0.81 | FFAR1 (0.47) | FFAR1HPGDTRPA1HTT | |
| SCHEMBL3634250 | 0.81 | PLAAT3 (0.49) | ALDH1A1FFAR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7533997 | 0.81 | ALDH1A1 (0.57) | ALDH1A1KEAP1FFAR1KMT2AMEN1 | |
| SCHEMBL27634594 | 0.81 | KEAP1 (0.55) | ALDH1A1KEAP1FFAR1KMT2AMEN1 | |
| SCHEMBL2334514 | 0.80 | AKR1B1 (0.58) | ALDH1A1KMT2AMEN1HDAC8HDAC6 | |
| SCHEMBL8507342 | 0.79 | KEAP1 (0.59) | ALDH1A1KEAP1FFAR1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2138500-B1 | Grignard reactions in microreactors | LONZA AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| US-7939698-B2 | Method for grignard type reactions in microreactors | LONZA AG (CH) | 2011-05-10 | — | — | US | disclosed |
| EP-2044087-B1 | GRIGNARD REACTIONS IN MICROREACTORS | LONZA AG (CH) | 2011-05-04 | — | — | EP | disclosed |
| EP-2138500-A1 | Grignard reactions in microreactors | LONZA AG (CH) | 2009-12-30 | — | — | EP | disclosed |
| US-20090270663-A1 | METHOD FOR GRIGNARD TYPE REACTIONS IN MICROREACTORS | LONZA AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-2044087-A2 | GRIGNARD REACTIONS IN MICROREACTORS | LONZA AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| EP-1889849-A1 | Grignard reactions in microreactors | LONZA AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008009378-A2 | GRIGNARD REACTIONS IN MICROREACTORS | LONZA AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270663-A1 | METHOD FOR GRIGNARD TYPE REACTIONS IN MICROREACTORS | GRIA4, GRM4, GRIK4 | ALDH1A1 2250/4885KEAP1 1271/4885FFAR1 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.